K Malcolm Maclure

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4146153/publications.pdf

Version: 2024-02-01

36 papers 4,293 citations

16 h-index 32 g-index

37 all docs

37 docs citations

37 times ranked

4627 citing authors

#	Article	IF	CITATIONS
1	The Case-Crossover Design: A Method for Studying Transient Effects on the Risk of Acute Events. American Journal of Epidemiology, 1991, 133, 144-153.	3.4	1,954
2	Triggering Myocardial Infarction by Marijuana. Circulation, 2001, 103, 2805-2809.	1.6	655
3	Triggering of Myocardial Infarction by Cocaine. Circulation, 1999, 99, 2737-2741.	1.6	403
4	Use of comorbidity scores for control of confounding in studies using administrative databases. International Journal of Epidemiology, 2000, 29, 891-898.	1.9	359
5	Control Sampling Strategies for Case-Crossover Studies: An Assessment of Relative Efficiency. American Journal of Epidemiology, 1995, 142, 91-98.	3.4	314
6	When should caseâ€only designs be used for safety monitoring of medical products?. Pharmacoepidemiology and Drug Safety, 2012, 21, 50-61.	1.9	123
7	â€~Why me?' versus â€~why now?'—differences between operational hypotheses in caseâ€control versu caseâ€crossover studies. Pharmacoepidemiology and Drug Safety, 2007, 16, 850-853.	^S 1.9	63
8	Deprescribing: Future directions for research. Research in Social and Administrative Pharmacy, 2019, 15, 801-805.	3.0	54
9	How the weather affects the pain of citizen scientists using a smartphone app. Npj Digital Medicine, 2019, 2, 105.	10.9	49
10	Case–crossover and case–time–control designs as alternatives in pharmacoepidemiologic research. Pharmacoepidemiology and Drug Safety, 1997, 6, S51-S59.	1.9	48
11	Control yourself: <scp>ISPEâ€endorsed</scp> guidance in the application of <scp>selfâ€eontrolled</scp> study designs in pharmacoepidemiology. Pharmacoepidemiology and Drug Safety, 2021, 30, 671-684.	1.9	36
12	Designed Delays Versus Rigorous Pragmatic Trials. Medical Care, 2007, 45, S44-S49.	2.4	24
13	Explaining pragmatic trials to pragmatic policy-makers. Cmaj, 2009, 180, 1001-1003.	2.0	24
14	"First-Wave" Bias When Conducting Active Safety Monitoring of Newly Marketed Medications with Outcome-Indexed Self-Controlled Designs. American Journal of Epidemiology, 2014, 180, 636-644.	3.4	18
15	DECISION-MAKING ALIGNED WITH RAPID-CYCLE EVALUATION IN HEALTH CARE. International Journal of Technology Assessment in Health Care, 2015, 31, 214-222.	0.5	17
16	Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada. BMJ Open, 2020, 10, e036102.	1.9	17
17	Measuring Prescribing Improvements in Pragmatic Trials of Educational Tools for General Practitioners. Basic and Clinical Pharmacology and Toxicology, 2006, 98, 243-252.	2.5	15
18	Outcomes associated with hospital admissions for accidental opioid overdose in British Columbia: a retrospective cohort study. BMJ Open, 2019, 9, e025567.	1.9	11

#	Article	IF	CITATIONS
19	Long-term Health Outcomes and Health System Costs Associated With Surgical Site Infections. Annals of Surgery, 2021, 273, 917-923.	4.2	11
20	Predicting postoperative surgical site infection with administrative data: a random forests algorithm. BMC Medical Research Methodology, 2021, 21, 179.	3.1	11
21	Bias in caseâ€crossover studies of medications due to persistent use: A simulation study. Pharmacoepidemiology and Drug Safety, 2020, 29, 1079-1085.	1.9	10
22	Reflecting on what? The difficulty of noticing formative experiences in the moment. Perspectives on Medical Education, 2018, 7, 379-385.	3.5	9
23	Physical Exertion Immediately Prior to Placental Abruption: A Case-Crossover Study. American Journal of Epidemiology, 2018, 187, 2073-2079.	3.4	9
24	Impact of drug cost sharing on service use and adverse clinical outcomes in elderly receiving antidepressants. Journal of Mental Health Policy and Economics, 2010, 13, 37-44.	0.6	7
25	Drug Insurance Utilization Management Policies and "Reference Pricing― An Illustrated Commentary on the Article by Vittorio Maio and Colleagues. Milbank Quarterly, 2005, 83, 131-147.	4.4	6
26	Policyâ€induced selection bias in pharmacoepidemiology: The example of coverage for Alzheimer's medications in British Columbia. Pharmacoepidemiology and Drug Safety, 2019, 28, 1067-1076.	1.9	5
27	Case–Crossover Designs for More Patientâ€Centred Epidemiology. Paediatric and Perinatal Epidemiology, 2014, 28, 77-78.	1.7	4
28	On the Evaluation of Drug Benefits Policy Changes with Longitudinal Claims Data. Disease Management and Health Outcomes, 2002, 10, 763-769.	0.4	2
29	Camouflaged sampling and contacting of people from administrative databases: reaching target patients without knowing who they are. Pharmacoepidemiology and Drug Safety, 2008, 17, 790-797.	1.9	2
30	Development and pilot evaluation of an educational session to support sparing opioid prescriptions to opioid naà ve patients in a Canadian primary care setting. Family Practice, 2022, 39, 1024-1030.	1.9	2
31	Délivrance d'opioÃ⁻des après un accouchement par césarienne en Colombie-Britannique : une analyse de cohorte historique de 2004 à 2019. Canadian Journal of Anaesthesia, 2022, 69, 997-1006.	1.6	2
32	Trends in opioid dispensing after common abdominal and orthopedic surgery procedures in British Columbia: a retrospective cohort analysis. Canadian Journal of Anaesthesia, 0, , .	1.6	2
33	AUDIOVERIFICATION OF SMALL DATASETS. American Journal of Epidemiology, 1983, 118, 779-780.	3.4	0
34	Mortality and the selfâ€controlled case series method. Response to Letter to Editor Pharmacoepidemiology and Drug Safety, 2012, 21, 907-907.	1.9	0
35	Abstract TMP95: Large Centralized TIA Assessment Unit Associated With Reduction of Recurrent Stroke by up to 70%. Stroke, 2016, 47, .	2.0	O
36	Using Simulated Data to Assess Case-Crossover Designs for Studying Less Transient Effects of Drugs. Drug Safety, 2017, 40, 757-760.	3.2	0

3